Another player has entered the market for the biosimilar Pegfilgrastim. Sandoz launches its version in the US market. Here, Biocon-Mylan's share is around 5 percent with around USD 15 million of sales. Kiran Mazumdar Shaw, chairman and MD of Biocon shared her views and outlook.
